Tesamorelin is a stabilised analogue of GHRH studied for its effects on visceral adipose tissue, GH secretion, and metabolic parameters in laboratory settings.
| Molecular Weight | 5135.0 g/mol |
| Purity | >98% |
| Form | Lyophilized powder |
| Storage | -20°C |
Science-backed research overview for this compound
Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH). It is specifically modified to be more stable and have a longer half-life than the natural hormone produced in the body.
Tesamorelin works by stimulating the pituitary gland to release Growth Hormone (GH). GH then triggers lipolysis (the breakdown of fat), with a unique affinity for visceral adipose tissue—the deep "belly fat" that surrounds internal organs and is linked to metabolic disease.
Tesamorelin is the only GHRH analogue approved for the reduction of excess abdominal fat in HIV patients with lipodystrophy. Research into this peptide is ongoing for its ability to improve metabolic health, reduce liver fat (NAFLD), and even enhance cognitive function in the elderly by increasing IGF-1 levels.